Compare Expensify Inc (EXFY) vs 10X Genomics Inc (TXG) Price & Performance

Expensify (EXFY) trades at $2.30, up 1.32% with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 and Q2 2026 earnings beats and positive operating cash flow of $20.09M in 2025. Recent business developments include AI-native ERP integrations and European card expansion, signaling growth initiatives. However, the stock carries a high P/E ratio of 258.82 and negative profitability metrics, presenting a mixed investment case.

The outlook remains cautiously optimistic with analyst consensus pointing to significant upside (target $13.75), but investors face risks from persistent net losses and competitive pressures. The key opportunity lies in the company's strategic pivot to AI-driven solutions and international expansion, though execution risks and valuation concerns warrant careful monitoring.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.